Work

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-204255

Authors: Binod Dhakal, Andrew J. Yee, Paul G. Richardson, Sikander Ailawadhi, Saurabh Chhabra, Eli Muchtar, Jesús G. Berdeja, Shambavi Richard, Jeffrey V Matous, Urvi A. Shah, Mark A. Schroeder, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Sagar Lonial

Institutions: Medical College of Wisconsin, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mayo Clinic in Florida, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic, Tennessee Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Colorado Blood Cancer Institute, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, C4 Therapeutics (United States), Emory University, Winship Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405040811

Cites:

Cited by: 6

Related to: 10